Biosimilar Product Information
This page contains links to product summaries of characteristics and patient information leaflets for the Fresenius Kabi range of biosimilar products. Please note all links are to a third party website and by clicking the links you will leave the Fresenius Kabi UK website.
Idacio® (adalimumab)
SmPC - Idacio 40mg solution for injection in pre-filled pen
Patient Leaflet(PIL) - Idacio 40mg solution for injection in pre-filled pen
SmPC - Idacio 40mg solution for injection in pre-filled syringe
Patient Leaflet(PIL) - Idacio 40mg solution for injection in pre-filled syringe
SmPC - Idacio 40mg/0.8mL solution for injection for paediatric use
Patient Leaflet(PIL) - Idacio 40mg/0.8mL solution for injection for paediatric use
Otulfi®⯆ (ustekinumab)
SmPC - Otulfi 130mg concentrate for solution for infusion
Patient Leaflet (PIL) - Otulfi 130mg concentrate for solution for infusion
SmPC - Otulfi 45mg solution for injection
Patient Leaflet (PIL) - Otulfi 45mg solution for injection
SmPC - Otulfi 45mg solution for injection in pre-filled syringe
Patient Leaflet (PIL) - Otulfi 45mg solution for injection in pre-filled syringe
SmPC - Otulfi 90mg solution for injection in pre-filled syringe
Patient Leaflet (PIL) - Otulfi 90mg solution for injection in pre-filled syringe
Tyenne®⯆ (tocilizumab)
SmPC - Tyenne 162mg solution for injection in pre-filled pen
Patient Leaflet (PIL) - Tyenne 162mg solution for injection in pre-filled pen
SmPC - Tyenne 162mg solution for injection in pre-filled syringe
Patient Leaflet (PIL) - Tyenne 162mg solution for injection in pre-filled syringe
SmPC - Tyenne 20mg/mL concentrate for solution for infusion
Patient Leaflet (PIL)- Tyenne 20mg/mL concentrate for solution for infusion
Reporting a side effect/adverse drug reaction
⯆ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly to the Yellow Card Scheme at https://yellowcard.mhra.gov.uk
By reporting side effects you can help provide more information on the safety of these medicines.
Adverse events should also be reported to Fresenius Kabi Limited. Email: Pharmacovigilance.GB@fresenius-kabi.com
GB-BOM-2600005 April 2026